EU-US trade talks: Focus on closer drug licensing collaboration
Trade negotiators are locked away in a room in Washington, poring over the details of a huge trans-Atlantic trade deal between the US and EU.
One of the aims of these talks is to make it easier for medicines licensed on one side of the Atlantic to be given the green light on the other.
Currently a drug approved for use in America could take two years or more before being approved in Europe, and vice-versa.
Jeremy Howell reports.
09 Jul 2013
- From the section Business